HZNP NASDAQ
Horizon Therapeutics Public Limited Company
1W: +0.3%
1M: +0.8%
3M: +12.9%
1Y: +71.3%
3Y: +45.2%
5Y: +513.7%
$116.30
Last traded 2023-10-09 — delisted
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Revenue Segmentation
By Product / Service
By Geography
Revenue by Segment (5-Year Trend)
Income Trends
Revenue
$3.6B
+12.5% ▲
5Y CAGR: +28.0%
Gross Profit
$2.7B
+11.4% ▲
5Y CAGR: +39.7%
Operating Income
$617M
+13.7% ▲
Net Income
$521M
-2.4% ▼
EPS (Diluted)
$2.22
-2.2% ▼
EBITDA
$1.1B
+22.6% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|
| Revenue | $1.2B | $1.3B | $2.2B | $3.2B | $3.6B |
| YoY Growth | +14.3% | +7.7% | +69.3% | +46.6% | +12.5% |
| Cost of Revenue | $422M | $362M | $533M | $795M | $920M |
| Gross Profit | $785M | $938M | $1.7B | $2.4B | $2.7B |
| Gross Margin | 65.0% | 72.1% | 75.8% | 75.4% | 74.6% |
| R&D Expenses | $83M | $103M | $209M | $432M | $438M |
| SG&A Expenses | $692M | $697M | $973M | $1.4B | $1.5B |
| Operating Expenses | $775M | $800M | $1.2B | $1.9B | $2.0B |
| Operating Income | $2M | $127M | $490M | $543M | $617M |
| Operating Margin | 0.2% | 9.7% | 22.3% | 16.8% | 17.0% |
| Interest Expense | $122M | $87M | $60M | $81M | $84M |
| Income Before Tax | -$119M | -$20M | $402M | $463M | $527M |
| Tax Expense | -$45M | -$593M | $12M | -$72M | $5M |
| Net Income | -$74M | $573M | $390M | $534M | $521M |
| Net Margin | -6.1% | 44.1% | 17.7% | 16.6% | 14.4% |
| EPS (Diluted) | $-0.45 | $2.90 | $1.81 | $2.27 | $2.22 |
| EBITDA | $286M | $314M | $739M | $909M | $1.1B |
| Shares Outstanding | 166M | 205M | 215M | 236M | 235M |